Description: Merck (MRK) closed at $111.01 in the latest trading session, marking a +2.54% move from the prior day.

Description: Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug can lift Q4 sales performance.

Description: US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while viewing subcutaneous PD-1s as a practical evolution in care delivery more than a major paradigm shift.Exton, PA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights reports new findings from its inaugural Market Dynamix™: PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S. oncologists. The research reveal

Description: TetraScience, the Scientific Data and AI company, today announced the appointment of Matt Studney as Chief Customer Officer. Studney is a seasoned business, R&D, and technology leader with more than two decades of experience operating at the intersection of science, data, and engineering.

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma

Description: 1416 ET – Disc Medicine management maintained that their engagement with the FDA about approval for bitopertin remains constructive in an analyst event at the JPMorgan Healthcare Conference, BMO says in a note. The company is looking to dispel investor jitters about an article in STAT News reporting that Center for Biologics Evaluation and Research Director Vinay Prasad is skeptical about the bitopertin application. 1238 ET – Merck & Co. CEO sees the opportunity for more than $5 billion in revenue from the company’s acquisition of Cidara, which has an antiviral influenza treatment known as CD388 in Phase 3 studies.

Description: AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.

Description: New drugs seen driving $70 billion by 2035

Description: Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.

Description: Merck KGaA (ETR:MRK) Chief Executive Officer Belén Garijo used the company’s presentation at the 44th J.P. Morgan Healthcare Conference to outline what she described as a “next wave of growth,” anchored by three strategic growth pillars: Process Solutions in Life Science, rare diseases in Healthcare

Description: Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build a 5 billion cell atlas over three years, and will be the most comprehensive map of human disease biology to date.

Description: ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.

Description: PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.

Description: We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]

Description: AbbVie has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs. The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development. AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.

Description: Investors Eye 2026 Guidance as Tempus AI Tops $1.1B in Contract Value

Description: The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Description: ABBV stock falls 3% in a month amid takeover rumor denials, but Skyrizi and Rinvoq momentum and a deep pipeline support staying invested.

Description: All three companies are in better shape than most investors are (understandably) presuming.

Description: CHICAGO, January 11, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma, including AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Novartis, Merck, Abbvie, Daiichi Sankyo, Eli Lilly, Boehringer Ingelheim, and biotechs inc

Description: Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a group of experimental cancer drugs.

Description: Even suggesting that the Dogs of the Dow could outperform the Magnificent 7 in 2026 seems ludicrous. The Dogs consist of stodgy, beaten-down stocks from the Dow Jones Industrial Average, often mature companies that have underperformed recently, leading to high dividend yields. In contrast, the Magnificent 7 represent elite Big Tech firms driving market gains ... Can the Dogs of the Dow Really Beat the Magnificent 7 in 2026?

Description: The company might become the latest biotech acquisition story soon.

Description: Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1% a

Description: Merck is in talks to acquire Revolution Medicines in a deal that could value it at around $30 billion, according to people familiar with the matter. A deal for the cancer-drug biotech could come as soon as later this month, the people said, cautioning the talks could still fall apart or another suitor could prevail. Merck has been discussing a deal valued between $28 billion and $32 billion, the people added.

Description: Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.

Description: All three major US stock indexes were up in late-morning trading Friday, after the US Bureau of Labo

Description: NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.

Description: JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.

Description: Revolution Medicines stock was soaring again early Friday after a report that Merck is in talks to buy the cancer-drug biotech for up to $32 billion.

Description: BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure

Description: These five Dogs of the Dow may be the perfect play for 2026 for growth and income investors wary of volatility and a potential sell-off.

Description: US equity futures edged higher ahead of Friday's opening bell as traders digested the crucial monthl

Description: Johnson & Johnson has said it will lower the price of some medications sold to U.S. consumers, making it the latest pharmaceutical company to form a business agreement with the Trump administration. “Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” Johnson & Johnson’s chief executive Joaquin Duato said in a statement late Thursday. Johnson & Johnson also said it will participate in the proposed patient platform, TrumpRx.gov, which will allow patients to buy drugs at “significantly discounted rates.”

Description: Small caps hit a new high Thursday as techs faltered. The December jobs report a possible Trump tariffs ruling loom Friday.

Description: US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in...

Description: Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best DOW Stocks to Buy in 2026. On January 5, Wells Fargo added Merck & Co., Inc. (NYSE:MRK) to its Q1 2026 Tactical Ideas List. Wells said Merck is moving into what it calls a catalyst-rich stretch across FY26 and 2027. The firm expects the […]

Description: Merck (MRK) concluded the recent trading session at $110.99, signifying a +2.2% move from its prior day's close.

Description: Investing.com -- Revolution Medicines (NASDAQ:RVMD) stock closed higher by 5% Thursday and added another 15% after-hours following a Financial Times report that Merck (NYSE:MRK) is in talks to acquire the biotech company.

Description: NEW YORK, January 08, 2026--GenNx360 Capital Partners ("GenNx360"), a New York City-based private equity firm investing in middle-market industrial and business services companies, today announced the appointment of Hany Salama as Chief Executive Officer of its portfolio company, Nutra-Med Packaging ("Nutra-Med" or the "Company"), one of the leading contract development and manufacturing organizations serving the health, wellness, and pharmaceutical sectors. Mr. Salama succeeds Kunal Gupta, effe

Description: Jan 8 () - Merck is in talks to ​buy cancer drug developer ‌Revolution Medicines, the Financial Times ‌reported on Thursday, citing people familiar with the matter. Shares of Revolution were ⁠up 5.

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: Investing.com -- Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already priced in much of AbbVie’s near- and medium-term upside.

Description: The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.

Description: The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Description: The Dow Jones Industrial Average is on the verge of another big milestone and could continue to climb as the rally broadens.

Description: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Description: These top BofA Securities stock picks are perfect for growth and income investors seeking dependable passive income from reliable companies.

Description: Merck (MRK) said Wednesday it has initiated a phase 3 clinical trial to evaluate calderasib combined

Description: RAHWAY, N.J., January 07, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a Phase 3 clinical trial evaluating calderasib (MK-1084), an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) for the first-line treatment of patients with KRAS G12C-mutant, advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).

Description: RAHWAY, N.J., January 07, 2026--Merck to Complete Acquisition of Cidara Therapeutics

Description: RAHWAY, N.J., January 07, 2026--Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3

Description: Merck (MRK) is back in focus after a trio of recent developments, including an upcoming J.P. Morgan Healthcare Conference fireside chat, encouraging KEYTRUDA ovarian cancer trial results, and a planned US$1b manufacturing investment in Delaware. See our latest analysis for Merck. Those KEYTRUDA updates, the Cidara tender offer and the big Delaware build out are landing against a backdrop of firming momentum, with Merck’s 30 day share price return at 7.74% and 90 day share price return at...

Description: NEW YORK CITY, NEW YORK / ACCESS Newswire / January 6, 2026 / Allison Worldwide and Stagwell (NASDAQ:STGW) are turbocharging their global communications capabilities and positioning for growth in healthcare with the appointment of industry veteran ...

Description: The TIGIT inhibitors market is poised for growth with the anticipated drug approval by 2030, over 40 drugs in clinical trials, and a dynamic landscape involving major pharmaceutical and biotech firms. Opportunities exist in enhancing cancer immunotherapy, particularly for tumor types resistant to current treatments, through combination regimens and biomarker-driven strategies.Dublin, Jan. 06, 2026 (GLOBE NEWSWIRE) -- The "TIGIT Inhibitors Drugs Clinical Trials & Global Market Opportunity Outlook

Description: Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Description: Merck & Co. will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Description: BioInvent International has reported encouraging interim Phase 2a results showing that combining its BI-1808 antibody with Merck’s KEYTRUDA improved response rates and maintained a favorable safety profile in patients with recurrent ovarian cancer. This early efficacy signal in a difficult-to-treat cancer adds another potential use case for KEYTRUDA, underscoring the importance of Merck’s immuno-oncology collaborations. Next, we’ll examine how this early ovarian cancer data for the...

Description: The highest-yielding stocks in the Dow are Verizon, Chevron, and Merck, but should you buy any of them?

Description: RAHWAY, N.J., January 05, 2026--Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Description: Robust expansion currently defines the landscape as major players like Eli Lilly and Merck aggressively fund new manufacturing facilities. Concurrently, the industry embraces rapid technological advancements in automated membrane filtration to streamline critical quality assurance processes.Chicago, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The global sterility testing market was valued at US$ 1,344.31 million in 2025 and is expected to reach US$ 3,913.35 million by 2035, growing at a CAGR of 11.36% dur

Description: 24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a favorable safety and tolerability profile Results ...

Description: Wondering if Merck at around $106 is still a smart buy or if most of the upside is already priced in? This breakdown will help you decide whether the market is being too cautious or not cautious enough. Despite a flat return year to date and a modest 1.6% gain over three years, the stock has climbed 6.7% in the last month and 11.4% over the past year, hinting that sentiment around Merck's long term prospects is quietly improving. Recently, attention has centered on Merck's late stage...

Description: The latest trading day saw Merck (MRK) settling at $106.45, representing a +1.13% change from its previous close.

Description: Investing.com -- Bank of America has released its new list of high-conviction U.S. stock ideas for the first quarter of 2026, featuring nine Buy-rated names and one Underperform.

Description: Novo Nordisk cuts Wegovy prices in China, which may shift investor focus toward diversified healthcare ETFs.

Description: We recently published 10 Market Stars Behind Millionaire-Making in 2025. Cidara Therapeutics Inc. (NASDAQ:CDTX) is one of the top performers. Cidara Therapeutics climbed by 721.76 percent in 2025, primarily bolstered by its looming merger with Merck for $9.2 billion. In an announcement last November, Cidara Therapeutics Inc. (NASDAQ:CDTX) said that it signed a definitive agreement […]

Description: List prices to rise an average of 4% despite federal pressure to curb costs.

Description: Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.

Description: Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 17, the US Food and Drug Administration moved to fast-track reviews of two experimental Merck & Co., Inc. (NYSE:MRK) drugs with multibillion-dollar potential, according to internal documents seen by Reuters. Merck’s cholesterol pill enlicitide decanoate […]

Description: AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.

Description: The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Description: JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.

Description: The latest trading day saw Merck (MRK) settling at $106.45, representing a +1.34% change from its previous close.

Description: Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.

Description: AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.

Description: BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.

Description: Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Description: We recently published 8 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radars. Pharma giant Merck & Co., Inc. (NYSE:MRK)’s shares are up by 1.9% year-to-date on the back of a strong run since early November. Before the run started, the stock was down 16.8% […]

Description: Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.

Description: Vaxcyte stock kept its place as one of Mizuho’s top picks entering 2026, with the firm reiterating an Outperform rating and a $163 price target in a research note. Vaxcyte is advancing to phase 3 trials for its shot, VAX-31, in adults and phase 2 trials for infants. It could eventually be a leader in an $8 billion market, Mizuho argued.

Description: The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.

Description: Kura Oncology, Inc. (NASDAQ:KURA) is one of the stocks Jim Cramer offered insights on. When a caller highlighted the company’s $135 million milestone payment owing to its U.S. commercial sale of KOMZIFTI, Cramer commented: “That’s a lot. That is a lot… Now, just understand that, yeah, they are milestone payments, not actual. Now, here’s what […]

Description: Dow Jones stock Merck and eight other bellwether pharma companies struck drug-pricing agreements with the Trump administration on Friday.

Description: New research highlights NVIDIA's AI-driven growth, Netflix's ad-tier momentum and Merck's pipeline progress, while microcaps also make the cut.

Description: President Trump announced deals with nine major drug makers in a move to reduce pharmaceutical prices, granting a three-year break on trade tariffs if they invest more into US manufacturing. Market Domination Overtime host Jared Blikre breaks down the news. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: The most recent pledges mean 14 of the 17 drugmakers targeted by Trump this summer have agreed to lower prices for the Medicaid program for low-income and disabled people, sell discounted drugs directly to consumers and launch new medicines for the same prices in the US as they do abroad. “American drug prices will come down fast and furious, and will soon be among the lowest in the developed world,” Trump said during an event in the Oval Office.

Description: Health care stocks rose late Friday afternoon, with the NYSE Health Care Index increasing 0.8% and t

Description: This year has been one to forget for these pharmaceutical giants.

Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer talked about recently. Cramer mentioned the stock during the episode and said: “These groups were the salvation of this market when the year of magical investing ended, and the super speculative stocks started coming back to earth, they’re still doing it, followed by the […]

Description: Nine pharmaceutical companies including Merck and GSK agreed to lower certain U.S. prices for their medicines in a new round of industry pacts with the Trump administration. The companies agreed to reduce U.S. prices on drugs to levels comparable with prices charged in other wealthy countries, which are generally much lower. Merck, for example, said it would make diabetes drugs Januvia and Janumet available to eligible American patients at a cash price that is 70% off the current list price through a direct-to-patient program.

Description: RAHWAY, N.J., December 19, 2025--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Description: As the U.S. stock market experiences a resurgence, with major indexes like the Nasdaq and S&P 500 seeing notable gains driven by tech shares, investors are keenly observing opportunities across various sectors. In this dynamic environment, dividend stocks stand out as a compelling option for those seeking consistent income streams alongside potential capital appreciation.

Description: Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.

Description: All three major US stock indexes were up in late-morning trading Friday, as the artificial-intellige

Description: MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.

Description: We recently published 12 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radar. Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world. Its shares are flat year-to-date and would have been lower had it not been for a run […]

Description: We recently published 12 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December […]

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: MSD declines to exercise option for EVX-B2 developmentEvaxion is now able to out-license EVX-B2 to another partnerEvaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studiesThere is no impact on Evaxion’s cash runway which extends to the second half of 2027 COPENHAGEN, Denmark, December 19, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has bee

Description: Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.

Description: ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced the closing of a $20 million Series A financing. Proceeds will be used to advance the company’s lead program into Phase 2 clinical development for obesity and diabetes, as well as other programs in IND-enabling stage and early preclinical stage. The financing was led by Lapam Capital, with participation from Frees Fund and Riverhead Capital. “This Seri

Description: In the latest trading session, Merck (MRK) closed at $100.69, marking a +1.52% move from the previous day.

Description: Wondering if Merck KGaA is a bargain hiding in plain sight or a value trap at €118.85? This article unpacks what the market is really pricing in. The stock has slipped 0.2% over the last week, but is up 6.4% over the past month, even though it remains down 15.3% year to date and 12.6% over the last year. That rebound has come as investors refocus on Merck's diversified footprint across healthcare, life science, and electronics, and its ongoing investments into high growth areas like...

Description: J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.

Description: Micron upgraded, PayPal downgraded: Wall Street's top analyst calls

Description: Pre-Market Stock Futures: Futures are trading higher on Thursday as we grind closer to the Christmas holiday, which is just a week off now. The song remains the same for the AI/Datacenter trade, and participants are finding it’s going to be a bit tougher here at the end of the year than in the last ... Here Are Thursday’s Top Wall Street Analyst Research Calls: Digital Realty, GE Vernova, Micron Technology, Merck & Co., Rivian, United Airlines, and More

Description: DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Description: We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Merck & Co., Inc. is among the most undervalued stocks. On December 12, 2025, Morgan Stanley analyst Terence Flynn reiterated an Equal Weight rating on MRK and raised the price target from $100 to $102 in a research note to […]

Description: <body><p>STORY: Coons noted that although regulatory changes have "weighed on some stocks within healthcare... we still like the weight-loss theme, particularly around Lilly."</p><p>The global obesity market has surged in recent years on strong demand for GLP-1-based drugs like Lilly's blockbuster drug Zepbound.</p><p>Lilly also produces Kisunla, a drug to slow Alzheimer's.</p><p>"When you're looking at Big Pharma, they're just way undervalued right now relative to the rest of the market," said Coons, who added, "we do like Merck as well."</p></body>

Description: Merck & Co., Inc. (NYSE:MRK) is included among the 12 Best Dogs of the Dow to Invest in. On December 15, BofA raised its price target on Merck & Co., Inc. (NYSE:MRK) to $120 from $105 and kept a Buy rating. The analyst said the stock is starting to look more appealing as the pipeline […]

Description: Merck (MRK) just cleared an important clinical hurdle, reporting strong Phase 3 KEYNOTE B15 results showing that KEYTRUDA plus Padcev improved survival outcomes for muscle invasive bladder cancer patients compared with standard chemotherapy and surgery. See our latest analysis for Merck. Despite the headline grabbing oncology wins and regulatory progress on drugs like Winrevair, Merck’s 90 day share price return of 21.11 percent has not yet translated into outsized long term total shareholder...

Description: Adagene jumps 13.8% after the FDA grants Fast Track Status to muzastotug with pembrolizumab for MSS metastatic colorectal cancer.

Description: It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive industry.

Description: RAHWAY, N.J., December 17, 2025--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial showed KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv), given as neoadjuvant and adjuvant treatment (before and after surgery), demonstrated a statistically signifi

Description: Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver.

Description: Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index falling 1.6% and

Description: Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Blue-Chip Stocks with Growing Dividends. On December 12, Morgan Stanley lifted its price target on Merck & Co., Inc. (NYSE:MRK) to $102 from $100. The firm kept an Equal Weight rating on the stock. In its 2026 outlook for the biopharma space, the firm […]

Description: Each company has a bullish case, but three stand out as great long-term buys.

Description: LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Description: If you are wondering whether Merck is still attractively priced today, or if the market has already priced in much of the potential upside, this is a good place to dig into what the numbers may indicate about its value. Merck’s share price is around $100.26, with gains of 1.3% over the last week, 7.9% over the last month, and 55.4% over five years. These moves highlight both resilience in the stock and changing expectations around its long term growth and risk profile. Recent headlines have...

Description: The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress continues globally with over 120 activated clinical sites and 27 countries having received full regulatory approvals including the United States Futility analysis remains on track for the first quarter of CY2026 and completion of patient enrolment in the third quarter of CY2026 SYDNEY, AUSTRALIA, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: I

Description: Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD

Description: Merck (MRK) is expected to deliver mid-single-digit revenue growth in fiscal 2026 driven primarily b

Description: Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.

Description: BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.

Description: By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its 2025 analyst day on December 9 th , 2025, at the Harvard Club in New York City. The morning presentations highlighted the company’s achievements for 2025 and looked ahead to 2026, providing financial guidance for the next year. Details of the event are included in a press

Description: Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

Description: Merck & Co., Inc.'s ( NYSE:MRK ) dividend will be increasing from last year's payment of the same period to $0.85 on...

Description: They could grow into their valuation over the next few years.

Description: BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.

Description: In early December 2025, Merck reported that the EMA’s Committee for Medicinal Products for Human Use recommended expanding WINREVAIR’s EU indication to cover adults with pulmonary arterial hypertension in WHO Functional Class II, III and IV, based on Phase 3 ZENITH data in high‑risk patients. This positive opinion, following recent U.S. label updates, strengthens WINREVAIR’s profile as a first‑in‑class activin signaling inhibitor and could broaden its clinical and commercial reach in severe...

Description: Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.

Description: RAHWAY, N.J., December 12, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval of an expanded indication for WINREVAIR™ (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III, and IV based on the Phase 3 ZENITH study. The cu

Description: Merck (MRK) closed at $99.01 in the latest trading session, marking a +1.42% move from the prior day.

Description: ABBV's expanding oncology lineup, spanning new solid tumor drugs and rising Venclexta sales, is helping drive steady top-line growth.

Description: ​Merck & Co., Inc. (NYSE:MRK) is one of the Cheap NYSE Stocks to Buy Now. On December 5, an analyst from Guggenheim raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $104 to $122 and maintained a Buy rating on the stock. ​A day earlier, on December 4, the company announced receiving […]

Description: Merck's updated narrative now anchors to a slightly higher fair value estimate of about $106.62 per share, up from roughly $104.27, as analysts grow more confident in the depth and durability of its pipeline. With revenue growth expectations trimmed only marginally and the discount rate left effectively unchanged at around 6.96%, the shift reflects nuanced optimism rather than a wholesale rerating. Stay tuned to see how you can keep track of these incremental adjustments as the story around...

Description: Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. The firm revealed that a Phase 2 study of efti in combination with radiotherapy and Merck’s Keytruda showed significant […]

Description: Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in. Guggenheim lifted the price target on Merck & Co., Inc. (NYSE:MRK) to $122 from $104 on December 5 while maintaining a Buy rating on the shares. The firm cited the inclusion of probability-adjusted revenues for Winrevair in the population investigated in […]

Description: Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.

Description: It looks like Merck & Co., Inc. ( NYSE:MRK ) is about to go ex-dividend in the next four days. The ex-dividend date is...

Description: The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) is a popular income choice for retirees. The fund generates income by holding a portfolio of dividend-paying U.S. stocks selected for their financial strength and dividend consistency. The ETF tracks the Dow Jones U.S. Dividend 100 Index, which screens for companies with at least 10 consecutive years of ... Schwab’s SCHD ETF Is Mostly Solid, But 1 Top Holding Is Concerning

Description: Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.

Description: Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.

Description: The company is finding ways to overcome the headwinds it will encounter in the medium term.

Description: Blockbuster drugs are a major driver of the growth of healthcare stocks.

Description: Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.

Description: The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly affecting older adults, is increasingly being treated with immune checkpoint inhibitors like Keytruda and Opdivo, which have revolutionized patient survival rates. The market faces challenges with the high cost of treatments impacting accessibility. Key players such as Merck, Bristol Myers Squibb, a

Description: TORONTO, December 09, 2025--BenchSci, a leading provider of AI software for biopharma research and development, today announced a renewed two-year contract with Merck, known as MSD outside of the United States and Canada.

Description: MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).

Description: The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi

Description: Merck and Duke Energy stand out as rare “safe yield” plays, pairing 3%+ dividends with solid earnings growth, reasonable payout ratios, and durable demand drivers in healthcare and regulated utilities.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Companies in The News Are: WBD, NFLX, MRK, VSCO, NRG

Description: Five market giants, CVNA, WMT, AMAT, FCX and MRK, delivered double-digit returns last month with more room to run in December.

Description: Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly funded adult immunization program. This addition supports increased access to pneumococcal immunization for eligible adults in accordance with the provincial eligibility criteria.

Description: Oppenheimer & Co. Inc., a leading investment bank, wealth manager and subsidiary of Oppenheimer Holdings (NYSE: OPY), today announced that Kostas Biliouris has joined the firm as Managing Director on its Biotech Research Team. He will report to William (Bill) Bird, Director of Research, and be based in New York City.

Description: Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted the company’s strategic planning for when Keytruda loses patent protection. He commented: “The people who run this company are not idiots. They’ve long known that Keytruda would lose patent protection, so, for years, they’ve been […]

Description: With yields between 3.4% and 6.8%, you'll need to think carefully about the highest yields in the Dow before you buy them.

Description: After a long hiatus, why are the bulls so willing to buy in now?

Description: Asia Pacific borrowers increased euro‑denominated issuance to a record 23% of the total across both currencies this year, up six percentage points from 2024, according to Bloomberg-compiled data. Multiple Asian deals ranked as the most oversubscribed in Europe’s publicly syndicated debt market during their launch week, the data showed. US dollar deals still make up the majority of financing deals, and borrowing in the greenback is up 29% by Asian issuers this year.

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]

Description: Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, a pioneer in temperature-controlled solutions for injectable medications, has entered into a distribution partnership with Salomo Executive, a leading healthcare logistics and consultancy company based in the Netherlands. This collaboration...

Description: These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?

Description: The rebound is well underway.

Description: After tepid performances throughout most of 2025, these stocks are showing some upward momentum.

Description: The Munich Regional Court ruled there was imminent infringement for Merck & Co.’s Keytruda SC in Germany related to Halozyme’s MDASE patents in Europe, the San Diego company said.

Description: We came across a bullish thesis on Merck & Co., Inc. on Darius Dark Investing’s Substack. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc.’s share was trading at $101.03 as of December 2nd. MRK’s trailing and forward P/E were 13.47 and 10.83 respectively according to Yahoo Finance. Merck & Co. (MRK) […]

Description: Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck to refrain from distributing and offering Keytruda SC in Germany.

Description: RAHWAY, N.J., December 04, 2025--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) has granted a conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution). This innovative product is in the newest class of parasiticides known as isoxazolines. The pour-on solution is effective for the prevention and treatment of infestati

Description: MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.

Description: RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking to make deals.

Description: CARMEL, Ind. & LONDON, December 04, 2025--Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel

Description: Merck (MRK) has quietly pulled ahead of many pharma peers, with the stock climbing about 22% over the past month and 20% in the past 3 months, drawing fresh attention to its valuation. See our latest analysis for Merck. That surge comes after a more muted stretch, with the share price now at $101.03 and a modest year to date share price return. However, a solid five year total shareholder return suggests long term holders have still done well. If Merck’s move has you rethinking opportunities...

Description: The nanopharmaceuticals market presents opportunities in addressing chronic diseases through enhanced targeted therapies and bioavailability. Personalization in treatments, particularly in oncology, is a key trend. However, high R&D costs and regulatory hurdles pose challenges. Key players include Merck, Pfizer, and Novartis. Nanopharmaceuticals Market Nanopharmaceuticals Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Nanopharmaceuticals Market - Global Industry Size, Share, Trends, Oppor

Description: Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: Investing.com -- Bernstein warned in a note Tuesday that “shock waves are expected at the ACIP meeting this week,” citing a series of unusual developments that could have implications for Merck, Pfizer and Moderna.

Description: Ever wondered if Merck’s current share price actually reflects its real worth? You’re not alone, and uncovering value can make all the difference for your portfolio. Merck’s stock has jumped 18.4% over the last 30 days, even though it’s dipped 3.6% over the last week. This shows just how quickly market sentiment can shift. This recent volatility comes as investors react to a wave of positive pipeline updates and strategic partnership announcements, which have fueled fresh optimism about...

Description: Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (

Description: Import taxes on medicines and treatments will remain at 0% for three years, the UK Government said.

Description: The Dow fell on the stock market today. Moderna skidded after an FDA memo linked Covid vaccines to deaths. A gold stock cleared an entry.

Description: Yields climbed by at least five basis points to the highest levels in about a week. The move accelerated during the US morning — led by long-maturity tenors, which ended about eight basis points higher — after Merck & Co. slated the largest of a slew of corporate bond offerings that totaled $15.8 billion.

Description: Marking World AIDS Day (December 1), and Giving Tuesday (December 2), (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS, announces today the return of 'The (RED) Holiday Edit'. The campaign runs through the holidays, ahead of (RED)'s 20th anniversary year in 2026 and with more than $800 million raised for the Global Fund thanks to extraordinary partners, people and products.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: RAHWAY, N.J., December 01, 2025--Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

Description: Key opportunities in the buffer preparation market include expanding demand for advanced buffer systems in biopharma production, increasing preference for outsourcing to reduce costs, and growth potential in reusable equipment and liquid formulations. North America remains dominant, while Asia-Pacific exhibits high growth potential. Scale of Operation Scale of Operation Buffer Service Providers Buffer Service Providers Buffer Manufacturing Systems Buffer Manufacturing Systems Dublin, Dec. 01, 20

Description: Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Boring Dividend Stocks to Buy. On November 24, Wells Fargo upgraded⁠ Merck & Co., Inc. (NYSE:MRK) to Overweight from Equal Weight, raising its price target to $125 from $90, according to a report by The Fly. The fi‍rm cited rece‌nt business developments, pipeline advance‌ment‍s, […]

Description: If you are thinking in decades and not days, this trio of dividend stocks could be the perfect starting point for your fledgling portfolio.

Description: There are plenty of potential winners outside the world of AI.

Description: The struggling pharmaceutical giant is showing signs of life.

Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer discussed, along with the need for diversification. Cramer highlighted that he is fond of the stock, as he said: “You could own JNJ and Merck with their incredible franchises. You know what? I’m actually particularly fond of JNJ right now. They’re spinning off their […]

Description: Investors will be weighing up how to shield their portfolios in case the rebound loses steam. These stocks look tempting.

Description: JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.

Description: Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.

Description: The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents challenges like relapse and treatment resistance, underscoring the need for novel treatment strategies. Innovative therapies such as monoclonal antibodies and CAR T-cell therapies are enhancing patient outcomes by providing more precise and less toxic options compared to traditional chemotherapy. Ke

Description: AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.

Description: Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Description: Merck has seen its fair value estimate edge higher to $104.27, up from $102.33, following recent updates to its growth outlook. Analysts cite an improved revenue growth expectation and a small uptick in the discount rate as drivers for this modest price target increase. This reflects a balance of positive developments and evolving risks. Stay tuned to discover how you can monitor shifts in Merck's story as new information emerges. Analyst Price Targets don't always capture the full story...

Description: In the past week, Merck received a boost as Wells Fargo upgraded its rating, citing increased confidence in Merck’s drug pipeline and noting significant progress in regulatory approvals for new oncology and HIV treatments. A key insight is that analysts see Merck’s pipeline advancements and diversified business development as easing concerns about future revenue risks associated with Keytruda’s eventual loss of exclusivity. With fresh optimism about Merck’s product pipeline and recent...

Description: MRK faces steep Gardasil declines as China and Japan demand soften, putting pressure on its vaccine portfolio.

Description: Merck has outperformed the healthcare sector over the past three months. Moreover, Wall Street analysts are moderately optimistic about its prospects.

Description: RAHWAY, N.J., November 26, 2025--Merck to Participate in the Citi 2025 Global Healthcare Conference

Description: RAHWAY, N.J., November 26, 2025--Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference

Description: The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks. Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation. Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.

Description: The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,

Description: Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Stocks to Buy for Medium Term. On November 17, BofA analyst Tim Anderson raised the firm’s price target on Merck & Co., Inc. (NYSE:MRK) to $105 from $98 and maintained a Bu⁠y ratin​g on the share‍s, as reported by The Fly. He‌ de​scribed the Cidara […]

Description: Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead.

Description: The U.S. government negotiated lower prices in the federal Medicare program for 15 high-selling medicines including Ozempic, widening an effort to rein in drug costs. The new prices, which will take effect in 2027, shave 38% to 85% off the list prices for drugs for diseases including asthma, cancer and diabetes. The reductions are estimated to save Medicare, the health-insurance program for the elderly, $12 billion.

Description: The Dow Jones Industrial Average and other major indexes ended Tuesday with hefty gains, as investors saw weak economic data as supporting a decision by the Federal Reserve to lower interest rates in December. Nvidia and Advanced Micro Devices slid on the stock market today on a report that Meta Platforms will use Google's AI chips. The Dow closed up 1.4%, or 664 points, despite Nvidia's 2.6% drop.

Description: VANCOUVER, BC / ACCESS Newswire / November 25, 2025 /Variational AI, a leading innovator in generative artificial intelligence for drug discovery, is making headlines in biotech with a bold mission: to reinvent early-stage drug discovery using AI-native ...

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Dairy Herd Management Market size & share revenue was valued at approximately USD 5.17 Billion in 2024 and is expected to reach USD 5.76 Billion in 2025 and is expected to reach around USD 15.23 Billion by 2034, at a CAGR of 11.37% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are DeLaval, Merck & Co. Inc

Description: Check out the companies making headlines yesterday:

Description: The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential approval in the first-line setting.

Description: As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.

Description: The Dow Jones index and the Nasdaq rise on the stock market today. Tesla jumps amid an AI boast by Elon Musk. Some health stocks test entries.

Description: Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells Fargo upgraded the stock to "Overweight" from "Equal-Weight," citing confidence in the company's future.

Description: Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.

Description: The Urinary Tract Infection (UTI) Treatment Market is projected to grow from US$ 9.13 Billion in 2024 to US$ 11.64 Billion by 2033, at a CAGR of 2.73%. This expansion is driven by rising UTI prevalence, awareness of early diagnosis, and advancements in therapy. Key growth factors include aging populations, rising catheter-associated infections, and a growing female demographic. Innovative treatments like vaccines and probiotics are gaining traction amid antibiotic resistance. North America leads

Description: Investing.com -- Merck shares received an upgrade at Wells Fargo, with analyst Mohit Bansa lifting the stock to Overweight and raising the price target to $125 per share in a note Monday, saying the firm “can see a future beyond Keytruda” as the company enters a catalyst-heavy stretch.

Description: Booking, Carvana upgraded: Wall Street's top analyst calls

Description: Pre-Market Stock Futures: The shortened holiday week is here, and the futures are trading higher this morning. Most traders and investors are returning with a severe case of whiplash after the stock market posted some of the wildest swings we have seen this year last week. Skyrocketing after the NVIDIA Corp (NASDAQ: NVDA) earnings and ... Here are Monday’s Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More

Description: RAHWAY, N.J., November 24, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company’s ongoing commitment to advancing clinical research in hematology across Merck’s expanding and diverse pipeline of investigational candidates

Description: Cidara Therapeutics Inc. (NASDAQ:CDTX) is the top stock in our list of the hottest SMID-cap stocks so far in 2025 with a 717% share price surge year-to-date. Following the acquisition announcement by Merck & Co. Inc. (NYSE:MRK), Guggenheim analyst Seamus Fernandez downgraded his rating on Cidara Therapeutics from Buy to Neutral on November 17, according to […]

Description: Merck & Co., Inc.'s ( NYSE:MRK ) periodic dividend will be increasing on the 8th of January to $0.85, with investors...

Description: Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Merck, Altria, and Genuine Parts have rewarded shareholders for years and recently announced dividend increases. These ...

Description: RAHWAY, N.J., November 22, 2025--Merck Recommends Rejection of Tutanota’s "Mini-Tender" Offer

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: Stock Market Today: The Dow Jones index rallied Friday after back-and-forth action. But Nvidia and Palantir couldn't pull ahead.

Description: RAHWAY, N.J., November 21, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who a

Description: Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health

Description: We recently published 13 Stocks That Crossed Jim Cramer’s Radar. Medtronic plc (NYSE:MDT) is one of the stocks Jim Cramer discussed. Medtronic plc (NYSE:MDT) is a medical technology company that makes and sells devices for cardiovascular, neuroscience, and surgical applications. Cramer has discussed the firm on a handful of occasions in 2025. One such discussion […]

Description: AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.

Description: Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.

Description: V benefits from rising cross-border volumes and strong digital payments momentum as analysts spotlight broad performance drivers across key sectors.

Description: As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding development of the cancer immunotherapy.

Description: Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory pressures.

Description: Health care stocks declined late Thursday afternoon with the NYSE Health Care Index and the Health C

Description: With its pipeline under pressure, Merck turns to Valo Health's AI brainpower in a high-stakes neuroscience push

Description: Valo will use its trove of patient records and biobank samples to pinpoint potential targets for Merck’s pipeline expansion.

Description: A Memorandum of Understanding (MOU) signed by the Virginia Innovation Partnership Corporation (VIPC) and AstraZeneca, Eli Lilly (Lilly), and Merck to develop the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) was executed by Governor Glenn Youngkin at a statewide gathering with key leaders from Virginia's life sciences ecosystem, higher-ed universities, and community colleges on October 31. This landmark public-private industry partnership commits $120 million of workforce inves

Description: For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date. It’s a challenge that Bristol Myers Squibb is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022. Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.

Description: Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.

Description: The pharmaceutical giant's post-Keytruda plans continue to take shape.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development.

Description: Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR® (sotatercept). The pCPA negotiates on behalf of the provinces, territories, and federal drug programs serving as a critical step in bringing WINREVAIR® closer to public reimbursement.

Description: Shares in the biotech company have surged on news of a big pharma takeover.

Description: Layoffs are increasing this year, and they're not limited to any one particular industry. We've previously seen high-profile layoffs from fast-growing technology stalwarts, including Amazon and Microsoft. Now, we've learned that Merck & Co., a 133-year-old drug manufacturer, also ...

Description: MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.

Description: The global astrocytoma market is poised for significant growth, anticipated to achieve substantial valuation by 2025 and expanding at a healthy CAGR from 2025 to 2035. This expansion is driven by the rising prevalence of high-grade astrocytomas and the increasing demand for effective treatments, including innovative immunotherapies and targeted therapies. Key growth areas include emerging markets such as Asia-Pacific, Latin America, and the Middle East, where healthcare improvements are rapidly

Description: The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula

Description: Merck (MRK) shares have ticked higher this week, catching the interest of investors who follow the big names in healthcare. The company's performance over the past month has been relatively steady. This stability invites a closer look at what might be driving sentiment. See our latest analysis for Merck. Merck’s momentum has picked up noticeably with a 1-month share price return of 13.7%, even as the year-to-date performance remains slightly negative. The stock’s 1-year total shareholder...

Description: GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit range JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the

Description: RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir [DOR/ISL (100 mg/0.25 mg)] in adults with HIV-1 infection who had not previously received antiretroviral treatment (treatment-naïve) (MK-8591A-053). The success criterion for the primary efficacy hypothesis, as measured

Description: RAHWAY, N.J., November 19, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved a new subcutaneous (SC), or under the skin, route of administration and a new pharmaceutical form (solution for injection) of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. KEYTRUDA SC™, as it will be marketed in the European Union (EU), [known as KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.]

Description: Pfizer Inc. (PFE) finally topped Novo Nordisk (NVO) to buy Metsera after Novo raised its bid twice. Metsera’s crown jewel is MET-097i, a weekly and monthly injectable GLP-1 asset that’s about to begin Phase III development, writes John McCamant, editor of Medical Technology Stock Letter.

Description: Merck stock jumped Tuesday on a surprise win for its drug, sotatercept, in patients with pulmonary hypertension.

Description: Dow Jones drug giant Merck is breaking out past its latest buy point as the stock market volatility continues Tuesday.

Description: RAHWAY, N.J., November 18, 2025--Merck Announces First-Quarter 2026 Dividend

Description: J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.

Description: The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.

Description: **Fanconi Anemia Market Growth Driven by Genetic Research and Healthcare Investments**Fanconi Anemia (FA) is a rare genetic disorder impacting bone marrow's ability to produce blood cells, leading to pancytopenia and increased cancer risk due to DNA repair defects. Although incurable, treatments like bone marrow transplants and gene therapy aim to manage FA's symptoms. The rising prevalence of genetic disorders and advancements in genetic research drive the FA market. Key players such as Rocket

Description: RAHWAY, N.J., November 18, 2025--Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With CpcPH due to HFpEF

Description: Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart in a study of adults with a common form of heart failure.

Description: J&J this year lost its patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease.

Description: Thinking about whether Merck is a bargain or not? You’re not alone, plenty of investors are eager to know if now is the time to buy, hold, or stay away. Over the last month, Merck’s share price has jumped 9.5% and gained 7.0% this week alone, even though it’s still down 6.4% year-to-date. Recent headlines have highlighted Merck’s expanding drug pipeline and a new FDA approval, fueling a bit of optimism and helping offset earlier caution in the market. These developments have given more...

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.

Description: Health care stocks were decreasing late Monday afternoon with the NYSE Health Care Index and the Hea

Description: Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.

Description: Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.

Description: SAN DIEGO, November 17, 2025--Solve Therapeutics Raises $120 Million to Develop Best-in-Class ADCs for Solid Tumors

Description: Investing.com -- Cidara Therapeutics was hit with broad downgrades after Merck agreed to buy the company for $221.50 a share in a deal valued at about $9.2 billion.

Description: The startup, which is backed by a dozen investors including Merck & Co., claims its novel “linkers” can help address some of the issues limiting the potential of earlier ADCs.

Description: Goldman Sachs is vying to capture its biggest share of the deals market in almost a quarter of a century, with Wall Street’s dominant investment...

Description: We recently published 10 Market Movers That Made Millionaires in a Week. Cidara Therapeutics Inc. (NASDAQ:CDTX) is one of the best-performing stocks of the past trading week. Cidara Therapeutics soared by more than 100 percent week-on-week, as investors repositioned portfolios following news that it is set to be acquired by Merck Co. for $9.2 billion. […]

Description: We recently published Lackluster Market? Not for These 10 Soaring Stocks. Cidara Therapeutics, Inc. (NASDAQ:CDTX) is one of the best-performing stocks on Friday. Cidara Therapeutics soared to nearly a decade high on Friday, as investors gobbled up shares following news that it is set to be acquired by pharmaceutical giant Merck for $9.2 billion. At […]

Description: Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Description: The Dow Jones Industrial Average fell Friday amid growing anxiety around the Federal Reserve's next

Description: Cidara Therapeutics shares doubled, and then some, on Friday after Merck agreed to buy the biotech company for $9.2 billion.

Description: Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Hea

Description: US equity indexes were mixed ahead of Friday's close amid selective dip-buying in technology and inf

Description: Merck agreed to pay $9.2 billion to purchase Cidara Therapeutics, looking to cash in on the firm's experimental flu treatment.

Description: ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today congratulated its former client, Cidara Therapeutics, on its acquisition ...

Description: US benchmark equity indexes were mixed intraday as the odds of a Federal Reserve rate cut continued

Description: US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec

Description: Gain insight on bidding wars in the pharmaceuticals sector, Novo Nordisk and more in the latest Market Talks covering the health care sector.

Description: Major U.S. equities indexes were mixed Friday afternoon, following a sharp decline Thursday fueled by a selloff of tech stocks.

Description: Yahoo Finance host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute, including tech names Nvidia (NVDA), Tesla (TSLA), and Broadcom (AVGO) in recovery mode from Thursday's tech sell-off, Merck's (MRK) plans to buy Cidara Therapeutics (CDTX) in a deal worth up to $9.2 billion, and Netflix (NFLX) prepares to execute its 10-for-1 stock split. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Description: The S&P 500 and Nasdaq Composite rose in midday trading, erasing earlier declines, and the Dow Jones

Description: Merck has agreed to pay a hefty premium for a biotech making a new flu prevention drug, as it braces for the expiration of the patents protecting its top-selling cancer treatment Keytruda. It is the latest signal that competition is intense as the biggest pharmaceutical companies scramble to pad their drug pipelines. Merck said Friday it will pay $9.2 billion for Cidara Therapeutics or $221.50 per share in cash, more than double the share price before the news.

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Merck (MRK) pursuing an acquisition of Cidara Therapeutics (CDTX) in a deal valued at $9.2 billion, the Wall Street Journal reporting that several media players are preparing bids on Warner Bros. Discovery (WBD), and StubHub (STUB) shares plunging after withholding its fourth quarter guidance. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: Merck has agreed a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antiviral that protects against flu, after overcoming...

Description: Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL

Description: US equity futures were down ahead of Friday's opening bell, extending losses from the previous sessi

Description: Merck (MRK) on Friday agreed to acquire immunotherapy developer Cidara Therapeutics (CDTX) in a deal

Description: Antipodes Partners recently published its “Antipodes Global Value Strategy” third-quarter 2025 investor letter, highlighting the key performance stocks, portfolio changes, and the market outlook. A copy of the letter can be downloaded here. In the quarter, global equities rose positively, supported by easing trade tensions, excitement around AI, and expectations of rate cuts by the […]

Description: Merck & Co. Inc. (NYSE:MRK) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 30, Merck & Co. Inc. (NYSE:MRK) announced its Q3 2025 earnings, showing better-than-expected financial results despite uneven product portfolio performance. The company’s revenue of $17.3 billion crossed analyst estimates of $16.98 billion, while its EPS […]

Description: Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...

Description: Fed members are openly having second thoughts about further cuts to interest rates, especially with no new data on the jobs or inflation front.

Description: Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: RAHWAY, N.J., November 13, 2025--Merck to Participate in the Jefferies Global Healthcare Conference in London

Description: Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock.

Description: Eli Lilly struck a deal with President Donald Trump last week that could send the stock much higher.

Description: In recent days, Merck announced pivotal Phase 3 trial results showing its once-daily oral PCSK9 inhibitor, enlicitide, reduced low-density lipoprotein cholesterol by more than half in patients with familial hypercholesterolemia and those at risk for atherosclerotic cardiovascular disease. The oral therapy’s effectiveness rivals that of injectable alternatives and could significantly expand intensive cholesterol-lowering options for patients who prefer pills over injections. We’ll explore how...

Description: Value-driven plays abound in the top healthcare stocks.

Description: Wall Street closed mixed on Tuesday, pulled up by healthcare, energy and consumer stocks.

Description: It's been a year to forget for these two companies, but brighter days are ahead.

Description: The main US stock measures were pointing higher in Wednesday's premarket activity as traders await a

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.

Description: As the U.S. stock market shows signs of optimism with major indexes rebounding on hopes for a resolution to the government shutdown, investors are keenly observing opportunities to strengthen their portfolios. In such an environment, dividend stocks can offer a compelling mix of income and stability, making them an attractive option for those looking to enhance their investment strategy amidst ongoing economic developments.

Description: Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.

Description: OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing Ampligen (rintatolimod), which was presented at the 40th Annual SITC Meeting on November 7, 2025, at National Harbor, MD. Platinum-sensitive patients with measurable peritoneal disease were eligible for combination therapy with up to six treatment cycl

Description: Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.

Description: RAHWAY, N.J., November 09, 2025--Merck’s Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 CORALreef HeFH Trial

Description: The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades. Now some patients have other cholesterol-busting medicines available as options—and even more alternatives are on the horizon. Certain patients already can take a twice-yearly injection, sold by Novartis as Leqvio, that uses an RNA-based technology, or a more frequent injection that targets a protein called PCSK9 that interferes with the body’s ability to clear the bad form of cholesterol.

Description: Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.

Description: RAHWAY, N.J., November 08, 2025--Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Description: Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best DRIP Stocks to Own Right Now. On November 3, Morg⁠an Stanley anal‌yst Tere‍nce Flynn‍ raised the price target for Merck & Co., Inc. (NYSE:MRK) from​ $98​ to $100 while maintaining an Equal Wei⁠g‍ht rating.​ He noted that third⁠-qu⁠arter re‍sults beat‌ exp‌ectations‍, largely due to […]

Description: Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: The overall market may be priced very richly here, but a handful of names haven't been swept up in artificial intelligence (AI)-driven mania.

Description: Despite revenue declines, Codexis Inc (CDXS) focuses on innovation and strategic partnerships to drive long-term success.

Description: DelveInsight's Endometrial Cancer Market Insights report includes a comprehensive understanding of current treatment practices, endometrial cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Description: Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2025. The company also provided a business update th

Description: MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment

Description: AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.

Description: The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.

Description: Planet Home, a company dedicated to building, launching and scaling Tough Tech companies, has announced the debut of the $1 million Planet Home Prize – a new global award recognizing breakthrough technologies redefining how we eat, make, move and live in balance with the planet.

Description: For traders with a neutral-to-slightly bullish outlook on Merck, a cash-secured put is one way to buy the stock at a discount.

Description: AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Precision Swine Farming Market size & share revenue was valued at approximately USD 810.34 Million in 2024 and is expected to reach USD 889.49 Million in 2025 and is expected to reach around USD 2061.6 Million by 2034, at a CAGR of 9.78% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are CTB Inc., YingZi,

Description: The Alliance for Building Better Medicine (ABBM) and the Virginia Innovation Partnership Corporation (VIPC) celebrated Governor Glenn Youngkin's announcement of $120 million in private industry investment from AstraZeneca, Eli Lilly, and Merck to establish the Virginia Center for Advanced Pharmaceutical Manufacturing (APM) in the Richmond-Petersburg-Charlottesville region. This neutral, industry-led Center will expand Virginia's workforce and training pipeline in collaboration with university an

Description: Merck (MRK) just announced a major deal with Blackstone Life Sciences, securing $700 million in funding to advance the development of its investigational cancer drug, sacituzumab tirumotecan. This fresh capital comes as Merck builds momentum with new product approvals and progress in expanding its pipeline. See our latest analysis for Merck. Merck’s share price has been on a bumpy ride this year, with recent funding and steady pipeline wins doing little to reverse the overall momentum. Total...

Description: Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the province of Quebec has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to their publicly funded adult immunization program. This addition makes the vaccine available to eligible residents in accordance with the province's eligibility criteria, helping to increase access to pneumococcal immunization.

Description: The funds will fuel continued Phase III clinical development of TROP-2 inhibitor sac-TMT.

Description: Lilly's GLP-1 drug became the best-selling drug on Earth in the third quarter.

Description: Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index and the Health Ca

Description: Investors were unimpressed with Merck's Q3 financial results.

Description: Precision oncology is tailoring treatments based on molecular profiles, while new surgical and radiotherapy methods boost recovery. Despite challenges like late diagnosis and high treatment costs, leading pharmaceutical companies are driving therapeutic innovation. Strategic alliances and investments in clinical trials are expected to enhance access to new treatments globally.Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Gastric Cancer Market - A Global and Regional Analysis: Focus on Treatment

Description: Wall Street ended mostly higher, with the Nasdaq and the S&P 500 finishing in positive territory, as investors once again flocked to artificial intelligence (AI) stocks following the announcement of a spate of new deals.

Description: The hyperlipidemia drugs market is growing due to rising cardiovascular disease prevalence, increasing cholesterol management awareness, and aging populations. Opportunities lie in personalized and combination therapies, digital health integration, non-statin alternatives, and expanding markets in Asia-Pacific. Hyperlipidemia Drugs Market Hyperlipidemia Drugs Market Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Hyperlipidemia Drugs Market Report 2025" has been added to ResearchAndMarkets.com's

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: Pre-Market Futures: The S&P 500 and NASDAQ futures are trading down over 1% on Tuesday, following Palantir’s 6.9% decline despite beating earnings expectations and giving strong forward guidance. Concerns over an AI bubble continue to mount. Tuesday’s sell-off follows a wild start to the week, during which the Dow Jones Industrial Average traded lower due ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More

Description: MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

Description: Morgan Stanley analyst Terence Flynn raised the firm’s price target on Merck (MRK) to $100 from $98 and keeps an Equal Weight rating on the shares. Q3 results beat expectations, but driven by one-timers and Januvia as Keytruda and Winrevair came in below expectations, the analyst tells investors. Merck guided to “solid” top line growth in 2026 from new launches, but also highlighted an acceleration in operating expense, notes the analyst, who models 2026 EPS of $9.44. Published first on TheFly –

Description: Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.

Description: After raising its 2025 profit forecast again, Pfizer turns its sights on Novo Nordisk in a billion-dollar obesity drug showdown.

Description: The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.

Description: RAHWAY, N.J., November 04, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences ("Blackstone") for the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP2), a protein found on the surface of various cancer cells. Merck is currently evaluating sac-TMT in 15 gl

Description: RAHWAY, N.J., November 04, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the company, through a subsidiary (Prometheus BioSciences), has reached an agreement with Dr. Falk Pharma GmbH (Falk) to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690 (formerly PRA-052), and for Merck to assume full responsibility for the development program going forward. MK-8690 is an inves

Description: The global veterinary monoclonal antibodies market is set to surge, reaching USD 3.06 billion by 2030, up from USD 1.70 billion in 2025, with a CAGR of 12.4%. This growth is driven by increasing pet ownership and heightened awareness of chronic diseases in pets. Despite challenges like rising pet care costs and strict regulations, expanding therapeutic uses offer new opportunities. Notably, the canine segment dominates due to the high incidence of skin conditions in dogs. By 2030, the subcutaneo

Description: With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies.

Description: Wondering if Merck stock is truly a bargain or just priced for perfection? You are not alone. Let's dig into what the numbers and recent developments say about its value. Despite a storied track record, Merck shares have pulled back lately, dropping 6.3% this past week, 7.5% over the last month, and now sit 16.8% lower for the year so far. Recent headlines have highlighted shifts in the pharmaceutical landscape, including regulatory news and developments with competitors in the oncology...

Description: The Dow Jones index fell but Amazon surged on deal with OpenAI. Kimberly-Clark plunged on the stock market today. Palantir popped.

Description: Executives in the rare earth elements market can leverage opportunities in electrification, defense, and renewable supply chains, address supply chain complexities, and capitalize on advances in separation and recycling technologies. A focus on sustainability, regional shifts, and strategic partnerships is crucial for navigating this evolving landscape. Rare Earth Elements Market Rare Earth Elements Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "Rare Earth Elements Market - Global Forecas

Description: RICHMOND, Va, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), congratulates Governor Glenn Youngkin, the Virginia Innovation Partnership Corporation (VIPC), and several leading Virginia universities on the recent announcement of a $120 million investment from AstraZeneca, Eli Lilly and Company, and Merck to expand Virginia’s life sciences and advanced pharmaceutical manufacturing workforce devel

Description: Sac-TMT will compete with two other TROP-2 targeted ADCs already approved: Gilead’s Trodelvy and AstraZeneca and Daiichi Sankyo’s Datroway.

Description: Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Description: RAHWAY, N.J., November 03, 2025--Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.

Description: Bayer and BI have reported broadly similar efficacy outcomes for sevabertinib and Hernexeos.

Description: Merck & Co Inc. (NYSE:MRK) is one of the best stocks to invest in, according to billionaire D.E. Shaw. On October 30, Merck & Co Inc. (NYSE:MRK) posted third-quarter 2025 sales of $17.3 billion, up 4% from last year. KEYTRUDA led the way with $8.1 billion in sales, rising 10%. WINREVAIR saw a sharp jump […]

Description: Merck & Co., Inc. ( NYSE:MRK ) last week reported its latest quarterly results, which makes it a good time for...

Description: Washington may be closed for business, but the economy keeps humming. Plus, investment newsletter commentary on housing-market troubles, the oil-price outlook, and attractive dividend stocks.

Description: The Craneware Group convened leaders from 25 major U.S. health systems, alongside representatives from Beacon/ESP (Berkeley Research Group) and Apexus, the HRSA 340B Prime Vendor, at its U.S. headquarters this week to align on readiness for the now-approved 340B Rebate Model Pilot Program.

Description: Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in 2026 Additional updates from the ongoing Phase 1b/2 trial with muzastotug, previously reported at ASCO 2025, are anticipated in the coming months SAN DIEGO and SUZ

Description: Merck (MRK) delivered annual earnings growth of 19.4%, outpacing its own 5-year average growth rate of 13.4%. Profit margins moved higher for the period, standing at 25.8% versus 22% last year, continuing a five-year streak of consistent profit expansion and pointing to persistent earnings quality. With the company currently trading below its estimated fair value and offering a lower Price-to-Earnings ratio than its peers, investors may see value. A strong dividend and history of growth...

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: ↘️ Chipotle Mexican Grill (CMG): The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were turning customers away from its stores. Shares slid 18% Thursday.

Description: Merck & Co Inc (MRK) reports a 4% revenue increase driven by Keytruda's demand, while facing headwinds in Gardasil sales and competitive pressures.

Description: Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.

Description: Investing.com -- Moderna (NASDAQ:MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about "a deal of significant scope," which could include a potential acquisition.

Description: Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan

Description: Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.

Description: Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer drug.

Description: Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 3.7% year on year to $17.28 billion. The company expects the full year’s revenue to be around $64.75 billion, close to analysts’ estimates. Its non-GAAP profit of $2.58 per share was 9.9% above analysts’ consensus estimates.

Description: The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Description: Health care stocks were flat to higher premarket Thursday, with the iShares Biotechnology ETF (IBB)

Description: Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Novo Nordisk's (NVO) bidding war with Pfizer (PFE) over who acquires Metsera (MTSR), Merck (MRK) cutting the higher end of its sales guidance, and Eli Lilly (LLY) raising its full-year revenue forecast after topping third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: US equity markets were tracking in the red before the opening bell Thursday as traders digest the ou

Description: Merck (MRK) delivered earnings and revenue surprises of +9.32% and +1.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Bristol Myers Squibb hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio. The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion. Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.

Description: Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, officially becoming the world’s best-selling drug.

Description: Investing.com - Merck has narrowed its full-year sales forecast, as a boost from an amended collaboration agreement with peer AstraZeneca and lower tariff costs was mitigated by costs connected to its purchase of Verona Pharma.

Description: RAHWAY, N.J. (AP) — Merck & Co. (MRK) on Thursday reported third-quarter earnings of $5.79 billion. The Rahway, New Jersey-based company said it had net income of $2.32 per share. Earnings, adjusted for one-time gains and costs, came to $2.58 per share.

Description: Merck reported higher third-quarter profit and boosted its full-year outlook, as demand for its flagship Keytruda cancer drug continues to rise.

Description: RAHWAY, N.J., October 30, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

Description: Market Domination Overtime host Josh Lipton previews several of the biggest stories to come tomorrow, Thursday, October 30, including earnings results from Big Tech names Apple (AAPL) and Amazon (AMZN), commentary from the Federal Reserve's Michelle Bowman, and the latest mortgage rates reading. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Merck shares have floundered this year, as the company speeds like a whistling locomotive toward the expiration of the patents protecting its megablockbuster cancer immunotherapy Keytruda. Executives have a shot at reassuring the market on Thursday, when the company reports its third quarter results, but analysts aren’t optimistic. “We see a choppy 3Q print,” Cantor analyst Carter Gould wrote early this month.

Description: Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.

Description: RAHWAY, N.J. & NUTLEY, N.J., October 29, 2025--Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

Description: RAHWAY, N.J., October 29, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adul

Description: Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.

Description: Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.

Description: Since the turn of the century, the Dogs of the Dow have significantly outperformed the overall market. These five are perfect plays for a slowing economy.

Description: The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its top-selling immunotherapy Keytruda loses patent protection.

Description: Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product’ strategy, leveraging her clinical and regulatory expertise to advance dencatistat, afirst-in-class CTPS1 inhibitor across multiple cancer and blood disorder indicationsAppointment follows Step Pharma’s recently announced €38 million Series C financing Saint-Genis-Pouil

Description: On October 27, 2025, Merck announced that the FDA approved an expanded label for WINREVAIR (sotatercept-csrk), allowing its use in adults with pulmonary arterial hypertension (PAH) to improve exercise capacity, functional class, and reduce risks of hospitalization, lung transplantation, and death. This regulatory milestone for WINREVAIR, supported by the Phase 3 ZENITH trial, highlights Merck's continued progress in broadening the clinical impact of its cardio-pulmonary portfolio. Next,...

Description: RAHWAY, N.J.,, October 28, 2025--Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy

Description: RAHWAY, N.J. & NUTLEY, N.J., October 28, 2025--Merck and Eisai Announce WELIREG® Plus LENVIMA® Met Primary Endpoint of PFS in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

Description: Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the federal government shutdown and GSK picked up a cancer drug.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?

Description: Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Description: RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.

Description: As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Description: One growth stock, one high-yield stock, and one Dividend King -- you should find something you like here as October draws to a close.

Description: J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.

Description: Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Description: Organon (OGN) said Monday its board has appointed the company's head of manufacturing and supply Jos

Description: JERSEY CITY, N.J., October 27, 2025--Organon (NYSE: OGN) ("Organon" or "the company") today announced that its Board of Directors has appointed the Company’s Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role. Director Robert Essner will assume the role of Lead Independent Director.

Description: RAHWAY, N.J., October 27, 2025--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label based on the Phase 3 ZENITH trial for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg. WINREVAIR, an activin signaling inhibitor, is now FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise

Description: Can the pharma giant offset potential losses from its megablockbuster with a strong suite of contenders?

Description: These bargains could prove good for your financial health.

Description: Evaxion (NASDAQ:EVAX) is one of the hot stocks to buy with huge upside potential. On October 20, Lake Street analyst Thomas Flaten raised the firm’s price target on Evaxion Biotech to $11 from $6 and kept a Buy rating on the shares. This sentiment was announced after the company announced two-year Phase 2 data for […]

Description: Market Domination Overtime host Josh Lipton previews several of the biggest stories to come next week, including earnings results from Magnificent Seven companies Microsoft (MSFT), Amazon (AMZN), Apple (AAPL), Alphabet (GOOG, GOOGL), and Meta Platforms (META); Federal Reserve officials convening for their October FOMC meeting; and President Trump is meeting Chinese President Xi Jinping in South Korea as the government shutdown nears its fifth week. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.

Description: LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.

Description: The United States lipid nanoparticle market is projected to expand from $210.34 billion in 2024 to $519.18 billion by 2033, with a CAGR of 10.56%. This growth is driven by the increasing use of lipid nanoparticles (LNP) in drug delivery, RNA-based therapies, and vaccines. Key factors include advancements in nanotechnology, increased pharmaceutical and biotech investments, and growing adoption of RNA therapeutics. Despite challenges like high production costs and regulatory complexities, strategi

Description: eschbach is pleased to share that Merck (NYSE: MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating Shiftconnector into its established visual factory framework, Merck is enhancing its ability to deliver real-time, actionable insights across global operations.

Description: Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer recently highlighted. Discussing the post-earnings rally of the stock, Cramer remarked: “Then there’s Danaher, DHR, the life sciences and diagnostic equipment company, which has been a huge disappointment for my Charitable Trust for so long. Not today, though. Today, Danaher gave us the quarter we’ve […]

Description: RAHWAY, N.J., October 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company’s cardio-pulmonary portfolio and pipeline at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, La., from November 7–10. Data presented at AHA highlight Merck’s continued dedication to advancing research across hypercholesterolemia and pulmonary arterial hypertension (PAH) to help address the global burd

Description: RAHWAY, N.J., October 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Padcev® (enfortumab vedotin-ejfv), for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are inel

Description: Merck (MRK) made headlines at the ESMO Congress by releasing new data from a suite of major Phase 3 clinical trials, each highlighting practice-changing advances for some hard-to-treat cancers. Results from Keytruda-based regimens included the first immune checkpoint inhibitor to show survival benefits in platinum-resistant recurrent ovarian cancer, improved outcomes in muscle-invasive bladder cancer, and extended event-free and overall survival for non-small cell lung cancer. See our latest...

Description: Danaher Corporation (NYSE:DHR) is one of the stocks in Jim Cramer’s recent game plan. Cramer showed slight optimism around the company’s upcoming earnings, as he remarked: “… and Charitable Trust club name Danaher, one of our biggest laggards, may report the first of many good quarters after a shocking multiple-year dry spell for this once […]

Description: Kenox Pharmaceuticals Inc. has announced the appointment of Dr. Julianne Berry as Vice President of R&D and Manufacturing. In her new role, Dr. Berry will oversee Kenox's integrated development, manufacturing, and testing operations, driving innovation and efficiency across the company's expanding portfolio of inhaled, nasal, and ophthalmic drug–device combination products.

Description: Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.

Description: New Elkton site to produce small molecule drugs and create 500 jobs.

Description: We recently published 10 Trending Stocks This Week. Merck & Co., Inc. (NYSE:MRK) is one of the trending stocks this week. Joseph Terranova, Senior Managing Director, Virtus Investment Partners, said in a recent program on CNBC that he recently bought Merck & Co Inc (NYSE:MRK). “I think at some point the market turns towards quality. […]

Description: The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include the rising diabetes prevalence, advancements in insulin delivery systems, and a surge in personalized diabetes solutions. Rapid acting insulin, essential for managing post-meal blood sugar surges, is favored for its quick efficacy. Innovations such as insulin pens and pumps, coupled with favorable he

Description: Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.

Description: The facility is part of the company’s $70bn US R&D and manufacturing expansion pledge.

Description: CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). FX-909, a first-in-class orally available small molecule inhibitor of PPARG, the master regulator of the lum

Description: The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.

Description: RAHWAY, N.J., October 21, 2025--Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE in U.S. Adults

Description: – Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile – STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for the treat

Description: Merck (MRK) closed the most recent trading day at $86.32, moving +1.8% from the previous trading session.

Description: Neuphoria Therapeutics (NEUP) said Monday that a phase 3 trial of BNC210 for the acute treatment of

Description: Health care stocks rose late Monday afternoon, with the NYSE Health Care Index and the Health Care S

Description: Health care stocks rose Monday afternoon, with the NYSE Health Care Index up 0.9% and the Health Car

Description: All three major US stock indexes were up in midday trading Monday ahead of big-name earnings this we

Description: ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.

Description: That's plenty of time for these drugmakers to move past their challenges.

Description: RAHWAY, N.J., October 20, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in treating non-small cell lung cancer (NSCLC). The results are based on the exploratory five-year analyses of KEYNOTE-671 evaluating KEYTRUDA as part of a neoadjuvant followed by adjuvant (perioperative) treatment regimen for patients with resectable NSCLC;

Description: Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion U.S. investment strategy.

Description: RAHWAY, N.J., October 20, 2025--Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

Description: A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study that could reshape first-line treatment regimens.

Description: BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy LUND, ...

Description: Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical significance Improvement in PFS favored the combination across virtually all subgroups, notably in patients with PD-L1-negative tumors, BRAFV600-mutated tumors, and elevated LDH, without adding any systemic toxicity compared to pembrolizumab alone

Description: BASKING RIDGE, N.J. & RAHWAY, N.J., October 19, 2025--Results from the phase 2 (dose optimization) part of the REJOICE-Ovarian01 phase 2/3 trial showed that raludotatug deruxtecan (R-DXd) demonstrated clinically meaningful response rates in patients with recurrent platinum-resistant ovarian, primary peritoneal or fallopian tube cancer. These data were presented today during a late-breaking proffered paper session (LBA42) at the 2025 European Society for Medical Oncology (#ESMO25) Congress.

Description: RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during

Description: Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of bladder cancer.

Description: RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 60% and reduced the risk of death by 50% when given before and after surgery (radical cystectomy) versus surgery alone, the current standard of care, in patients with muscle-invasive bladder cancer (MIBC) who are not eligible f

Description: RAHWAY, N.J. & NUTLEY, N.J., October 18, 2025--KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial Carcinoma

Description: Merck faces a sharp Gardasil slowdown as weak demand in China and Japan affects sales of the vaccine.

Description: ​Merck & Co., Inc. (NYSE:MRK) is one of the Best Forever Stocks to Invest In Now. On October 10, Tim Anderson of Bank of America Securities reduced the firm’s price target on Merck & Co., Inc. (NYSE:MRK) from $99 to $98, while keeping a Buy rating on the stock. ​The firm sees the company as […]

Description: Merck will offer its complete portfolio of IVF therapies through the president’s direct-to-consumer platform, TrumpRX, and boost manufacturing in the US. The most widely used drug, Gonal-f, is currently “700% more expensive in the United States than in the rest of the world,” Trump said during a press conference in the Oval Office on Thursday.